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Profiling human embryonic stem cell differentiation<p>Transcriptional p ofil ng of human embryonic stem cells differentiating into blast cells reveals that erythroblasts are the predominant cell type in the blast cell population. I  silico c mparisons with publicly available data set ed the presence of endo lia, card omy-ocytes d hematopoi tic lineages.</p>
Abstract
Background: Microarrays are being used to understand human embryonic stem cell (hESC)
differentiation. Most differentiation protocols use a multi-stage approach that induces commitment
along a particular lineage. Therefore, each stage represents a more mature and less heterogeneous
phenotype. Thus, characterizing the heterogeneous progenitor populations upon differentiation
are of increasing importance. Here we describe a novel method of data analysis using a recently
developed differentiation protocol involving the formation of functional hemangioblasts from
hESCs. Blast cells are multipotent and can differentiate into multiple lineages of hematopoeitic cells
(erythroid, granulocyte and macrophage), endothelial and smooth muscle cells.
Results: Large-scale transcriptional analysis was performed at distinct time points of hESC
differentiation (undifferentiated hESCs, embryoid bodies, and blast cells, the last of which generates
both hematopoietic and endothelial progenies). Identifying genes enriched in blast cells relative to
hESCs revealed a genetic signature indicative of erythroblasts, suggesting that erythroblasts are the
predominant cell type in the blast cell population. Because of the heterogeneity of blast cells,
numerous comparisons were made to publicly available data sets in silico, some of which blast cells
are capable of differentiating into, to assess and characterize the blast cell population. Biologically
relevant comparisons masked particular genetic signatures within the heterogeneous population
and identified genetic signatures indicating the presence of endothelia, cardiomyocytes, and
hematopoietic lineages in the blast cell population.
Conclusion: The significance of this microarray study is in its ability to assess and identify cellular
populations within a heterogeneous population through biologically relevant in silico comparisons
of publicly available data sets. In conclusion, multiple in silico comparisons were necessary to
characterize tissue-specific genetic signatures within a heterogeneous hemangioblast population.
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The establishment of human embryonic stem cells (hESCs)
raised the possibility of being able to treat/cure many human
diseases that are nowadays untreatable. This therapeutic
potential, however, largely relies on the efficient and control-
led differentiation of hESCs towards a specific cell type and
the generation of homogeneous cell populations. Many differ-
entiation protocols utilize the formation of progenitors
through a stepwise approach. Thus, characterizing and
understanding mixed populations of progenitor stages will be
of increasing importance in stem cell research.
hESCs have been shown to be able to differentiate into a vari-
ety of cell types, including hematopoietic precursors and
endothelial cells, in vitro under various culture conditions [1-
9]. Hemangioblasts are the precursors of both hematopoietic
and endothelial cells [10]. The existence of hemangioblasts
was first demonstrated using an in vitro differentiation sys-
tem of mouse ESCs. Replating of embryonic bodies (EBs) of
mouse ESCs resulted in the formation of blast colony forming
cells (BL-CFCs), which possessed hemangioblastic character-
istics: BL-CFCs generated both hematopoietic and endothe-
lial cells upon transfer to appropriate conditions [11,12]. Cells
with hemangioblastic characteristics have been reported in
both mouse and human adult tissues [13-18]. In an hESC sys-
tem, Wang et al. [3] found that a fraction of a percent (0.18%)
of CD45negFVP cells with hemangioblast-like properties in
hESCs derived from EBs. Zambidis et al. [8] demonstrated
the formation of multi-potential colonies from hEBs,
although it is unclear whether these colonies can be expanded
and/or whether they have any functional activity in vivo.
Umeda et al. [19] also identified the presence of CD34+/
KDR+ bipotential cells in non-human (Cynomolgus) ESCs.
Kennedy et al. [20] recently reported the generation of BL-
CFCs from hESCs. However, the rarity of the cells with
hemangioblast properties both from adult tissues and from
ESC systems precluded comprehensive analysis of gene
expression and comparison with other populations.
We have recently developed a two-step strategy that can effi-
ciently and reproducibly generate blast colonies (BCs), the
human counterparts of BL-CFCs, from hESCs [21]. These BC
cells expressed gene signatures characteristic of hemangiob-
lasts, and could be differentiated into multiple hematopoietic
cell lineages as well as endothelial cells. When the BC cells
were injected into animals with spontaneous type II diabetes
or ischemia/reperfusion injury of the retina, they homed to
the site of injury and showed robust reparative function of the
damaged vasculature. The cells also showed a similar regen-
erative capacity in NOD/SCID β2-/- mouse models of both
myocardial infarction (50% reduction in mortality rate) and
hind limb ischemia, with restoration of blood flow in the lat-
ter model to near normal levels, demonstrating the functional
properties of hemangioblasts in vivo [21]. In contrast to pre-
vious studies, these cells could be readily obtained in large
scale, which allowed us to perform comprehensive analysis of
gene expression in these cells and compare this with other cell
populations from which the BC cells originated.
Microarrays assess the total amount of RNA in a population
and can be influenced by a predominating cell type. Variation
in the homogeneity of the population can influence the
number of genes identified as differentially expressed. Here,
we show how comparisons to publicly available tissues in sil-
ico can identify differentially expressed genes representative
of the various cell types within a heterogeneous population.
In the current study, we analyzed the global gene expression
profiles with robust multi-chip average (RMA) normalization
to provide a relative value of gene expression between two
samples. The first analysis consisted of direct comparisons
with ESCs and their derivates (EBs and BCs). Genes enriched
in BCs relative to hESCs revealed a genetic signature indica-
tive of erythroblasts, suggesting that erythroblasts are the
predominant cell type in the BC population. The next analysis
consisted of multiple but biologically meaningful in silico
comparisons to publicly available data sets that identified
other progenitor cell types within the BC population. The sig-
nificance of this microarray study is in its ability to assess and
identify heterogeneous cellular populations through biologi-
cally relevant in silico comparisons.
Results
Strategy
Microarrays assess the total amount of RNA in a population
and can, therefore, be influenced by a predominating cell
type. Variations in the homogeneity of the population can
influence the number of genes identified as differentially
expressed, especially if both populations are relatively homo-
geneous. Here, we show how comparisons to publicly availa-
ble tissues in silico can identify differentially expressed genes
representative of the various cell types within the heterogene-
ous population of BCs.
We describe our method of assessing heterogeneous samples
in three levels of analysis. The first level consists of making
direct comparisons within the ESCs and their differentiated
derivatives (EBs and BCs). The advantage of this technique is
that it provides a kinetic-like relationship of changes in gene
expression upon differentiation. The second level of analysis
consists of indirect comparisons to a baseline, or reference
tissue. Breast epithelium was chosen as a reference tissue
because it represents a genetically distinct cell type that BCs
are not capable of differentiating into. ESCs, EBs, and BCs
were compared to breast epithelial tissue and differentially
expressed genes were compared and contrasted to each other.
Because genes that are up-regulated in BCs when compared
to breast epithelia could represent those that are under-
expressed in breast tissue, we removed those that were also
up-regulated in a genotypically similar but different cell type
(hESCs), when compared to breast epithelia.Genome Biology 2007, 8:R240
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sues they are capable of differentiating into as a way to mask
that cell type's 'genetic signature' and reveal signatures of the
more minor cell types. Samples were chosen based on type of
GeneChip and their public availability - leukocytes, and
endothelial and stromal cells. These biologically relevant
comparisons identified tissue specific genetic signatures that
would have otherwise been missed in the level I and II
analyses.
The reliability of the microarray data generated from our
multi-comparison analysis is demonstrated by the consistent
identification of a set of genes among multiple comparisons,
of which a subset of genes were confirmed by immunocyto-
chemistry (Table 1) and RT-PCR (Figure 1). To summarize,
comparing BCs to leukocytes identified genes involved in vas-
culogenesis, to endothelial cells identified genes involved in
hematopoiesis, and to stromal cells identified genes involved
in heart development.
Level I analysis
Genes down-regulated upon differentiation of ESCs into EBs and BCs
We began our data analysis by verifying the expression of
'stemness' genes that are down-regulated in ESCs upon dif-
ferentiation into EBs and BCs. We identified 87 genes that
were down-regulated upon differentiation into EBs. Genes
with the highest fold change include SOX2, LEFTY1, GAL,
NODAL, OCT4, and THY1, which play a critical role in main-
taining the undifferentiated status of ESCs [22-24]. To
uncover enriched processes, data sets were analyzed by
DAVID, a web-based tool that identifies over-represented
biological themes in a data set based on their Gene Ontology
(GO) terms. GO provides consistent descriptions of genes in
terms of biological processes and molecular function. When
these genes were clustered with DAVID based on their GO
terms, processes involved in development, cell differentia-
tion, and proliferation were identified. The genes identified in
the development ontology were DNA methyltransferase 3B,
FGF2, THY1, SFRP2, LEFTY1, GREM1, and NODAL (Addi-
tional data file 3).
We also identified 267 genes that were down-regulated upon
differentiation of ESCs to BCs. These genes include GAL,
TDGF, NANOG, LEFTY1, and OCT4, most of which are stem-
ness genes [22-24]. When genes were clustered with DAVID
using their GO terms, the processes included development,
cell differentiation, and morphogenesis (Additional data file
4). These data demonstrate that OCT4, NODAL, GAL, and
THY1 are initially down-regulated in stage 1 (ESCs→EBs) and
are further down-regulated in stage 2 (EBs→BCs).
Genes up-regulated upon differentiation of ESCs into EBs
While the focus of this paper is to evaluate the pathways
involved in hemangioblast differentiation, we begin by iden-
tifying those genes that were up-regulated in the early stage of
differentiation into EBs (day 3.5) from which BCs were
derived [21]. We identified 128 genes that were up-regulated
upon differentiation of ESCs into EBs (Additional data file 5).
These genes include HAND1, WNT5, HEY1, LMO2, BMP4,
TBX3, and MYL4. Clustering these genes with EASE identi-
fied processes involved in development, transcription, organ
development and system development, some of which are
related to hemangioblastic differentiation. These genes
include SOX9, HOXB2, HOXB3, Neuregulin 1, LMO2 [25]
and GATA2 [26]. This data set also included numerous genes
encoding transcription factors, such as MESP1, HAND1,
TBX3, GATA2, SOX7, SOX9, HOXB2, and HOXB3.
Genes down-regulated upon differentiation of EBs into BCs
When EBs were compared to BCs, 185 genes were identified
as down-regulated upon differentiation. This data set con-
tained processes that were similar to those that were down-
regulated upon ESC differentiation into EBs, such as tissue
and organ development. The most significantly down-regu-
lated genes included NANOG, WNT5, OCT4, GAL, TDGF1,
BMP4, endothelin receptor B, and VEFG (Additional data file
Validation of differentially expressed genes by RT-PCR in human ESCs, EBs and BCsFigure 1
Validation of differentially expressed genes by RT-PCR in human ESCs, EBs 
and BCs. (a) Total RNA from human ESCs, EBs and BCs was used to 
construct cDNA pools, and the expression of genes was examined by 
semi-quantitative PCR. The number at the top of each lane indicates the 
amount (microliters) of cDNA used in the 50 μL PCR reaction. M = 100 
bp DNA ladder. (b) Direct and (c) indirect analysis of differentially 
expressed genes matched the expression patterns obtained by RT-PCR. 
The fold change data are presented on the y-axis using logarithm-base-10.Genome Biology 2007, 8:R240
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initially up-regulated upon differentiation into EBs but then
down-regulated upon further differentiation into BCs.
Genes up-regulated upon differentiation of EBs into BCs
In contrast, 82 genes were up-regulated upon differentiation
of EBs into BCs. The genes with the greatest fold change were
hemoglobin genes and erythropoietic genes, such as hemo-
globins γ, ζ, α, and ε, Alas2, AFP, TUBB1, GYPA, and RHAG
(fold change, (FC) 31x-886x). Genes with moderate increases
in expression (FC 6.2x-7.2x) were KLF1, TAL1/SCL, GATA1
and CD71. When genes were clustered with DAVID using
their GO terms, processes characteristic of erythropoiesis
(heme and porphyrin biosynthesis and oxygen transport)
were identified (Additional data file 7).
Genes up-regulated upon differentiation of ESCs into BCs
There were 107 genes up-regulated upon differentiation of
ESCs into BCs. Similar to the data set above (EBs→BCs), the
genes with the greatest fold change (FC 29x-810x) were
involved in hemoglobin synthesis (hemoglobins γ, ε, and α,
ALA2, GYPA, and TAL1/SCL), similar to the comparison of
EBs to BCs. In addition, this data set contained many key
transcription factors involved in hemangioblastic
differentiation, such as GATA2 [26], LMO2 [25] and TAL1/
SCL [27,28] (Additional data file 8). GATA2 and MYL4 were
Table 1
Characterization of hESCs and BCs by immunocytochemistry and Affymetrix arrays
Level I Level II Level III
IC BC direct Epithelium Leukocytes Endothelium Stromal
GATA1 + + + + + +
GATA2 + + + -- -- --
CD71 + + + + -- +
EPO-R + -- + + + +
TPO-R + -- -- -- -- +
LMO2 + + + + -- +
β-Catenin + -- -- -- -- --
EGR1 + -- -- -- -- --
Integrin α4 +/- -- -- -- -- --
Integrin β1 +/- -- -- -- -- --
VE-cadherin -- -- -- + -- --
E-cadherin -- -- -- -- -- --
KDR -- -- -- -- -- --
PECAM (CD31) -- -- -- + -- --
CD34 -- -- -- + -- --
CD41 -- -- CD41b -- CD41b CD41b
CD43 -- -- -- + + +
The reliability of the microarray data generated from our multi-comparison analysis is demonstrated by the consistent identification of a set of genes 
among multiple comparisons, of which a subset of genes were confirmed by immunocytochemistry. For immunochemistry (IC): +, moderate to 
strong staining; -, negative staining; +/-, very weak staining. For Affymetrix arrays:+, detected as up-regulated in BCs; --, not detected as up-regulated 
in BCs.
Table 2
Gene ontologies for up-regulated processes in BCs versus ESCs
Gene category List hits EASE score
Oxygen transport (erythrocytic) 6 1.69E-09
Gas transport (erythrocytic) 6 1.69E-09
Transcription from Pol II promoter 7 1.64E-02
Regulation of transcription from Pol II promoter 5 2.38E-02
Development (developmental) 15 2.56E-02
EASE analysis of up-regulated genes in BCs identified biologically relevant themes, such as oxygen and gas transport, and development.Genome Biology 2007, 8:R240
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constant level upon differentiation into BCs. EASE analysis of
up-regulated genes in BCs identified biologically relevant
themes, such as oxygen and gas transport, and development
(TAL1/SCL, KLF1, LMO2, GATA1; Table 2).
Level II analysis
Genes enriched in ESCs
Since genes that are up-regulated in ESCs when compared to
breast epithelia could represent those genes that are under-
expressed in breast epithelium, we filtered out those that
were also up-regulated in BCs when compared to breast epi-
thelium. This analysis identified 2,108 genes, which com-
prised GO processes involved in cell cycle, DNA and RNA
metabolism, and DNA replication, as expected (Additional
data file 9). Genes with the highest fold change include
TDGF1, GAL, LEFTY1/2, OCT4, and NANOG (FC 130.0x,
69.6x, 68.7x, 47.6x, 43.8x, and 31.5x). When this data set was
clustered based on their GO terms, processes involved in
development, cell differentiation and nervous system devel-
opment were identified (data not shown). This data set was
then analyzed with GenMapp, and then used for pathway
analysis. Each genetic signature was assigned a color: ESCs,
green; EBs, orange; and BCs, red. The ESC pathway confirms
that most of the embryonic genes were not removed when
compared to breast epithelial cells (Additional data file 1).
Genes enriched in EBs
Since genes up-regulated in EBs when compared to breast
epithelia could similarly represent those that are under-
expressed in breast epithelium, we also filtered out those that
were also up-regulated in ESCs when compared to breast epi-
thelium. We identified 939 genes as up-regulated in EBs rel-
ative to breast epithelium and filtered out those that are
enriched in ESCs relative to breast epithelium (Additional
data file 10). When these genes were clustered with DAVID,
processes involved in development, transcription, wnt and
frizzle signaling, cell cycle and blood vessel morphogenesis
(KDR, VEGF, Neuropilin-1 and 2, and FLT1) were identified
The EBs also express genes involved in organ development,
suggesting a heterogeneous mixture of cell types (GATA2/4/
5/6, BMP4, NCAM1, NOG, ISL2, NKX2.5), and mesoderm
genes (HAND1, T-brachyury, MESP1). Further examination
of the data set identified multiple genes involved in the BMP
signaling pathway in the differentiation of blood and
endothelial cells. These genes include BMPR1A, BMP4, T-
brachyury, KDR, GATA2, and TAL1/SCL [26,28].
Genes enriched in BCs
We identified 2,735 genes that were up-regulated in BCs rela-
tive to breast epithelium after removing genes that were
enriched in ESCs when compared to breast epithelium and
genes enriched in BCs when compared to breast epithelium
(Additional data file 11). When genes were clustered based on
their GO, we identified processes characteristic of lym-
phocytic cells (response to stimulus, defense response,
immune response), erythrocytes (heme and porphyrin bio-
synthesis), coagulation, neurophysiology, development, and
mesoderm and heart development (Table 3).
Genes that were up-regulated in BCs with respect to epithelia
were characteristic of hematopoiesis (CD markers 5/6/9/38/
41/48/55/71/74/84/244, EPOR, GATA1/2/4/5, Tcr-α, natu-
ral cytotoxicity triggering receptor-1, 2 and 3), coagulation
(coagulation factor II, V, VII, XII, coagulation factor 2
receptor like 2,3/thrombin receptors, antithrombin 3,
cyclooxygenase 1, plasminogen), cardiac muscle (NKX2.5,
HAND1/2, GATA4, SOX6, TBX5), smooth/skeletal muscle
(NOTCH1, smoothelin, acetylcholinesterase, desmin, SOX6),
synaptic markers (cholinergic receptor, muscarinic 2 and 5,
adrenergic α-1A-receptor, dopamine receptor D2, serotonin
receptor 1B and 4, glutamate receptor Nmda 1 and 2A/B and
C, gaba A receptor β1 and 2, purinergic receptor P2X 1 and
2), and hemangioblasts (GATA2 [26], RUNX1 [29], LMO2
[25] and TAL1/SCL [27,28]). Some of the genes identified in
the coagulation ontology are not only involved in coagulation
but also angiogenesis, such as thrombin [30], plasminogen
[31], and possibly coagulation factor 2 receptor like 2/3 [30].
This was also recapitulated by DAVID analysis, which identi-
fied the following pathways as statistically over-represented:
porphyrin metabolism, acute myocardial infarction,
hematopoietic cell lineage pathways and calcium signaling
pathways. GenMapp was then used for pathway analysis.
Each genetic signature was assigned a color: ESC, green; EBs,
orange; and BCs, red. GenMapp analysis of pathways
involved in whole blood, bone marrow, coagulation and com-
plement, heme and porphyrin synthesis are indicative of
hematopoietic cell types (Figure 2). Genes identified in Gen-
Mapp's heme biosynthesis pathway are indicative of erythob-
lasts (Figure 3). We also identified myogenic (cardiac and
smooth) pathways, which correlates with the GO analysis.
Level III analysis
Genes enriched in BCs relative to leukocytes
We identified 2,101 genes that were up-regulated in BCs rela-
tive to leukocytes (after removing genes that were enriched in
both hESCs and BCs when compared to leukocytes (Addi-
tional data file 12). When these genes were clustered based on
their GO, we identified processes involved in development,
nervous system development, blood vessel development and
angiogenesis, and erythrocytes (Table 4). The presence of
development ontology not only indicates a 'progenitor' status
of BCs, but contains genes involved in hemangioblast devel-
opment, such as LMO2, TAL1/SCL, and RUNX1. This com-
parison identified genes that are characteristic of endothelia
(PECAM1, VE-Cadherin, CD34, vWF, EPOR [32], endothelin
1 [33], and thrombin receptor). There were also genes that
indicate the presence of erythrocytes (GATA1, spectrin and
ankyrin), blood vessel development (neuropilin-1 and 2, sta-
bilin 1 and 2, EGFR, FGF1 and 6, NOTCH4), and neurons/
neuronal junctions (glutamate receptor 1/6, serotoninGenome Biology 2007, 8:R240
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Gene ontologies of up-regulated processes in BCs versus epithelial cells
Gene category List hits EASE score
Response to external stimulus (lymphocytic) 146 5.14E-09
Cellular process 490 4.74E-06
Response to biotic stimulus (lymphocytic) 94 4.87E-06
Ion transport 68 7.05E-06
Defense response (lymphocytic) 87 1.09E-05
Development (developmental) 165 5.05E-05
Hemostasis 19 1.15E-04
Blood coagulation (coagulation) 18 1.68E-04
Cell-cell signaling 60 2.23E-04
Response to abiotic stimulus (lymphocytic) 60 3.74E-04
Cyclic-nucleotide-mediated signaling 19 3.92E-04
Morphogenesis (developmental) 101 4.23E-04
Response to light 26 5.54E-04
Natural killer cell activation (lymphocytic) 6 7.08E-04
Second-messenger-mediated signaling 20 8.47E-04
Perception of light 25 9.29E-04
Synaptic transmission (neurophysiology) 31 9.63E-04
Cell communication 244 1.07E-03
Cation transport 46 1.46E-03
Transmission of nerve impulse (neurophysiology) 31 1.61E-03
Transport 159 1.65E-03
Response to radiation 26 1.73E-03
Organogenesis (developmental) 88 2.09E-03
Metal ion transport 36 2.15E-03
Perception of abiotic stimulus (lymphocytic) 35 2.34E-03
Vision 23 2.54E-03
Immune response (lymphocytic) 68 3.77E-03
Perception of external stimulus (lymphocytic) 37 4.60E-03
Cell surface receptor linked signal transduction 93 5.44E-03
Xenobiotic metabolism 10 6.19E-03
Sensory perception 34 6.34E-03
Heme biosynthesis (erythrocytic) 5 6.40E-03
Response to xenobiotic stimulus 10 8.00E-03
Skeletal development (development) 18 8.65E-03
Potassium ion transport 19 8.71E-03
G-protein signaling 15 9.32E-03
Pigment biosynthesis (erythrocytic) 6 1.10E-02
Monovalent inorganic cation transport 29 1.15E-02
Heme metabolism (erythrocytic) 5 1.16E-02
Negative regulation of natural killer cell activity (lymphocytic) 3 1.28E-02
Regulation of natural killer cell activity (lymphocytic) 3 1.28E-02
Anion transport 15 1.49E-02
Heart development (heart development) 6 1.63E-02
Histogenesis (developmental) 16 1.85E-02
Porphyrin biosynthesis (erythrocytic) 5 1.90E-02
Pigment metabolism (erythrocytic) 6 1.95E-02Genome Biology 2007, 8:R240
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gin 2, myelin basic protein, peripheral myelin protein 22).
Of particular note is the absence of leukocytic processes, such
as response to stimulus and defense response identified in the
level two analyses. Thus, this comparison allowed for the
masking of the 'lymphocytic' signature and, thus, the identifi-
cation of other endothelial and blood vessel development
genes (vWF, bradykinin receptor b1, and thrombin recep-
tor). When this data set was analyzed using GenMapp, more
endothelial genes were mapped to the coagulation cascade
pathway (vWF, bradykinin receptor b1, thrombin receptor-
pathway; data not shown).
Genes enriched in BCs relative to endothelial cells
We identified 904 genes that were up-regulated in BCs rela-
tive to prostate-derived endothelium after filtering out those
genes that are enriched in ESCs relative to endothelium
(Additional data file 13). Comparing BCs to endothelial cells
identified fewer genes when compared to other comparisons
of BCs in level II and III analyses, and, thus, identified fewer
GO terms. However, it did identify more erythrocytic
processes (nine in total; Table 5) than the other comparisons.
Another predominant theme in this data set was development
(Table 5). By comparing BCs to a more mature yet similar cell
type (adult endothelium), we were able to mask the endothe-
lial signature, thus identifying predominantly development
genes (indicating stem/progenitor type signature), such as
caudal type homeobox transcription factor 2 (CDX2), delta-
like homolog (DLK1), lamin A/C, secreted frizzled-related
protein 5 (SFRP5), patched (PTCH), dishevelled 2 (DVL2),
and even-skipped homeobox homolog 1 (EVX1).
Pigmentation (erythrocytic) 6 2.30E-02
Mesoderm development (mesoderm development) 7 2.37E-02
Cellular defense response (lymphocytic) 13 2.44E-02
Response to pest/pathogen/parasite (lymphocytic) 43 2.63E-02
When genes were clustered based on their GO, we identified processes characteristic of lymphocytic cells (response to stimulus, defense response, 
immune response), erythrocytes (heme and porphyrin biosynthesis), coagulation, neurophysiology, development, and mesoderm and heart 
development.
Table 3 (Continued)
Gene ontologies of up-regulated processes in BCs versus epithelial cells
GenMAPP of complement and coagulationFigure 2
GenMAPP of complement and coagulation. Genes that are up-regulated in BCs (red), EBs (orange), and ESCs (green) compared to breast epithelia as 
baseline were mapped onto a pre-existing pathway. This pathway contains genes that are mostly up-regulated in BCs relative to breast epithelia.Genome Biology 2007, 8:R240
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The BCs were then compared to prostate-derived stromal
fibromuscular (CD49a immunoselected) tissue. This compar-
ison identified the most number of genes (3,277 genes;
Additional data file 14), and had the most diverse GO terms
(lymphocytic, developmental, erythrocytic, coagulation, syn-
apses and neurogenesis, and heart development; Table 6).
This data set contained lymphocytic processes according to
their GO (response to stimulus, defense response) and
numerous lymphocytic markers (CD 6/38/41/43/48/55/61/
71/84/244, immunoglobulin genes heavy constant γ1, con-
stant κ, constant λ1, and CD 158A/B/D/F/H (killer cell
immunoglobulin-like receptor)). This comparison identified
genes involved in hemangioblast differentiation (TAL1/SCL,
LMO2, RUNX1), endothelial genes (neuropilin 1 and 2), and
coagulation genes (fibrinogen α and β chain, coagulation
factor 5, plasminogen, but not KDR, FLT1, CD4, PECAM, VE-
Cadherin, vWF). Although EASE analysis for both epithelial
and stromal comparisons identified similar heart GO terms,
the stromal comparison identified different heart
development genes, such as MEF2C, aortic preferentially
expressed (APEG1), POU6F1, TBX1, and ryanodine receptor
2 (cardiac).
When these genes were clustered for pathways analysis with
DAVID, we identified Nfat, hypertrophy of the heart and Alk
in cardiac myocytes as a statistically over-represented path-
way (data not shown). GenMapp identified a similar pathway
involved in myometrial contraction and calcium regulation in
the cardiac cell (data not shown). These genetic signatures
from this analysis would indicate the presence of progenitors
(indicated by the number of developmental genes) of erythro-
cytes, leukocytes, neurons/neuronal-muscular junctions, and
cardiomyocytes. Thus, comparing BCs to stromal cells
masked a connective tissue-like signature, allowing for the
identification of tissue-specific processes.
Ingenuity analysis
To identify signaling pathways involved in hemangioblast dif-
ferentiation, each of the data sets was analyzed by Ingenuity.
Ingenuity is a program that converts large data sets into net-
works containing direct and indirect relationships between
genes based on known interactions in the literature. Genetic
networks were created using the EB and BC data sets. The EB
data set from the level 2 analysis contained a network of genes
(VEGF, GATA4, BMP4) that are interconnected and involved
in blood vessel development (VEGF), heart development
(GATA4), and cellular development (BMP4) (Figure 4a). For
example, Bmp-4 has been shown to promote blood vessel
development by increasing VEGF production [34] and VEGF
induces or binds to KDR FLT1, NRP1, and NRP2 [35-38]. This
network suggests that BMP4 inhibits cardiac development by
increasing HEY1, a transcriptional repressor of GATA4 and 6
(Figure 5a) [39,40], and inhibits heart development by induc-
ing DKK1 (dickkopf homolog 1) [41], which then inhibits
WNT11 mRNA expression, GATA4, and NKX2-5 [42-44]. In
conclusion, this network suggests that BMP4 induces blood
vessel development through VEGF signaling and inhibits car-
diac differentiation through HEY1 and DKK1.
We then looked for these and other signaling pathways in the
level 2 BC data set. Here we identified genes involved in car-
diovascular development (SHH [45], RAR-B, TBX5 [46],
WNT11 [43]) acting through GATA4 (Figure 4b). However,
unlike the EB data set, we did not identify the cardiac repres-
sor HEY1, VEGF and BMP4 in the BC data set. Instead, the BC
network contained cardiac and skeletal genes, such as
HAND2 and ANKRD1 [47-50], and HIF3A, an inhibitor of
VEGF expression [51] (Figure 5b). Thus, these networks dem-
onstrate that when EBs differentiate into BCs, we see some
angiogenic and some cardiac pathways.
Another signaling network we identified as differentially
expressed between EBs and BCs is the network containing
GATA2. GATA2 has been shown to play a vital role in heman-
gioblast development [26] by up-regulating BMP4, KDR, and
TAL1/SCL expression. In the EB data set, the GATA-2 net-
GenMAPP of heme biosynthesis: Genes that are up-regulated in BCs (red), EBs (orange), and ESCs (gre n) compared o breast pithelia as baseline w re m pped onto a heme bio ynthesis p hwayFigure 3
GenMAPP of heme biosynthesis: Genes that are up-regulated in BCs (red), 
EBs (orange), and ESCs (green) compared to breast epithelia as baseline 
were mapped onto a heme biosynthesis pathway. This pathway contains 
genes that are up-regulated in BCs relative to breast epithelia.Genome Biology 2007, 8:R240
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Gene ontologies for up-regulated processes in BCs versus leukocytes
Gene category List hits EASE score
Development (developmental) 178 6.39E-09
Morphogenesis (developmental) 116 1.98E-08
Organogenesis (developmental) 105 5.04E-08
Cellular process 482 6.48E-08
Cell communication 257 4.78E-07
Cell adhesion 68 4.05E-06
Skeletal development (developmental) 25 4.44E-06
Cell-cell signaling 64 4.86E-06
Ion transport 62 8.10E-05
Circulation 20 9.47E-05
Metal ion transport 38 2.53E-04
Cartilage condensation 6 3.56E-04
Cation transport 46 5.97E-04
G-protein coupled receptor protein signaling pathway 61 8.03E-04
Regulation of blood pressure 9 9.06E-04
Neurogenesis (neuronal) 46 1.17E-03
Second-messenger-mediated signaling 19 1.32E-03
Cell surface receptor linked signal transduction 93 1.52E-03
Bone remodeling 9 2.01E-03
Ossification 9 2.01E-03
Cell homeostasis 15 2.07E-03
Cell ion homeostasis 14 2.27E-03
Ion homeostasis 14 2.27E-03
Transition metal ion transport 9 2.40E-03
Transport 151 2.97E-03
Homeostasis 15 3.10E-03
Transition metal ion homeostasis 7 3.37E-03
Receptor mediated endocytosis 7 4.20E-03
Metal ion homeostasis 11 4.48E-03
Homophilic cell adhesion 15 5.91E-03
Di-, tri-valent inorganic cation homeostasis 10 6.86E-03
Gas transport (erythrocytic) 5 7.51E-03
Oxygen transport (erythrocytic) 5 7.51E-03
Cation homeostasis 12 8.76E-03
Angiogenesis (blood vessel development) 8 1.10E-02
Cyclic-nucleotide-mediated signaling 15 1.13E-02
Transmission of nerve impulse (neurophysiology) 27 1.16E-02
Monovalent inorganic cation transport 28 1.19E-02
Di-, tri-valent inorganic cation transport 14 1.42E-02
Enzyme linked receptor protein signaling pathway 21 1.42E-02
Synaptic transmission (neurophysiology) 26 1.42E-02
Blood vessel development (blood vessel development) 8 1.44E-02
Iron ion homeostasis 5 1.64E-02
Blood coagulation (coagulation) 13 1.80E-02
Tyrosine kinase signaling pathway 15 1.99E-02
Signal transduction 177 2.18E-02
Potassium ion transport 17 2.47E-02Genome Biology 2007, 8:R240
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6a). Pitx2 is a homeobox gene involved in regulating the bal-
ance between proliferation and differentiation of progenitor
cells [52] and is highly expressed in EBs (FC 24x) and is
absent in BCs. PITX2 is not only rapidly down-regulated
upon hematopoietic stem cell differentiation [52], but may
also promote hemangioblast differentiation by inducing
GATA2 expression [53]. In the BC data set, the GATA2 net-
work contained the hemangioblastic and hematopoeitic
genes TAL1/SCL and LMO2 [25,27,54], FOG/Zfpm1[55],
CD41/GPIIB/Igta2B [56] and GATA1 [57] (Figure 6b).
A predominant network we identified in all three data sets of
the level III analysis involved GATA1. GATA1 is a globin tran-
scription factor and is present in all BC but not EB data sets.
For example, we see GATA1 interacting with other nuclear
Hemostasis 13 2.77E-02
Pregnancy 8 2.89E-02
Axon guidance (neurophysiology) 6 4.00E-02
When these genes were clustered based on their GO, we identified processes involved in development, nervous system development, blood vessel 
development and angiogenesis, and erythrocytes.
Table 4 (Continued)
Gene ontologies for up-regulated processes in BCs versus leukocytes
Table 5
Gene ontologies for up-regulated processes in BCs versus endothelial cells
Gene category List hits EASE score
Development (developmental) 84 2.10E-05
Oxygen transport (erythrocytic) 6 2.14E-05
Gas transport (erythrocytic) 6 2.14E-05
Heme biosynthesis (erythrocytic) 5 2.88E-04
Heme metabolism (erythrocytic) 5 5.56E-04
Morphogenesis (developmental) 51 6.08E-04
Organogenesis (developmental) 46 9.55E-04
Porphyrin biosynthesis (erythrocytic) 5 9.66E-04
Porphyrin metabolism (erythrocytic) 5 1.55E-03
Transport 77 1.89E-03
Pigment biosynthesis (erythrocytic) 5 2.83E-03
Pigment metabolism (erythrocytic) 5 4.70E-03
Pigmentation (erythrocytic) 5 5.46E-03
Hemostasis 9 9.09E-03
Learning and/or memory 4 1.67E-02
Skeletal development (developmental) 10 1.69E-02
Response to chemical substance 14 1.87E-02
Blood coagulation (coagulation) 8 2.05E-02
Hearing 7 2.16E-02
Perception of sound 7 2.29E-02
Synaptic transmission (neurophysiology) 14 2.69E-02
Ion transport 26 3.17E-02
Cell-cell signaling 25 3.20E-02
Cellular process 204 3.21E-02
Transmission of nerve impulse (neurophysiology) 14 3.36E-02
Response to abiotic stimulus (lymphocytic) 25 3.88E-02
Cartilage condensation 3 3.89E-02
Circulation 8 4.64E-02
Coenzyme and prosthetic group metabolism 9 4.98E-02
This comparison did not identify as many genes because of their similar origin and thus fewer gene ontologies. However, it did identify more 
erythrocytic processes than the other comparisons.Genome Biology 2007, 8:R240
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Gene ontologies for up-regulated processes in BCs versus stromal cells
Gene category List hits EASE score
Cell communication 328 7.47E-07
Cellular process 617 1.25E-06
Cell-cell signaling 79 4.71E-06
Response to external stimulus (lymphocytic) 160 1.38E-05
Ion transport 74 4.07E-04
Response to abiotic stimulus (lymphocytic) 72 4.61E-04
Transport 199 8.97E-04
Cation transport 56 1.08E-03
Defense response (lymphocytic) 95 1.09E-03
Metal ion transport 44 1.30E-03
Response to biotic stimulus (lymphocytic) 101 1.35E-03
Development (developmental) 192 1.55E-03
Intracellular receptor-mediated signaling pathway 8 1.72E-03
Organogenesis (developmental) 108 1.98E-03
Cell adhesion 72 2.17E-03
Morphogenesis (developmental) 118 2.98E-03
Synaptic transmission (neurophysiology) 35 3.04E-03
Signal transduction 238 4.29E-03
Transmission of nerve impulse (neurophysiology) 35 5.07E-03
Regulation of blood pressure 9 5.42E-03
Monovalent inorganic cation transport 36 6.29E-03
Steroid hormone receptor signaling pathway 7 6.65E-03
Homeostasis 17 6.77E-03
Cell surface receptor linked signal transduction 113 8.56E-03
Perception of abiotic stimulus (lymphocytic) 39 1.09E-02
Hemostasis 17 1.10E-02
Second-messenger-mediated signaling 20 1.18E-02
Potassium ion transport 22 1.19E-02
Cyclic-nucleotide-mediated signaling 18 1.24E-02
Blood coagulation (coagulation) 16 1.39E-02
Response to chemical substance (lymphocytic) 31 1.45E-02
Heme biosynthesis (erythrocytic) 5 1.48E-02
Gas transport (erythrocytic) 5 2.00E-02
Oxygen transport (erythrocytic) 5 2.00E-02
Neurogenesis (neuronal) 51 2.02E-02
Cell homeostasis 15 2.31E-02
Perception of external stimulus (lymphocytic) 41 2.41E-02
Estrogen receptor signaling pathway 4 2.48E-02
Heme metabolism (erythrocytic) 5 2.61E-02
Homophilic cell adhesion 16 2.74E-02
Pigment biosynthesis (erythrocytic) 6 2.84E-02
Circulation (erythrocytic) 17 2.94E-02
Olfaction 9 3.02E-02
Response to pest/pathogen/parasite (lymphocytic) 52 3.19E-02
Acute-phase response (coagulation) 6 3.43E-02
Skeletal development 19 3.72E-02
Sensory perception 37 3.86E-02Genome Biology 2007, 8:R240
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erythropoetic genes such as the hemoglobin family (HBG1,
HBG2, HBE, HBB, and HBZ), heme synthesis (ALAS2), and
genes expressed on the cell surface of RBC (Ankyrin 1, Rh
blood group, glycophorin A, erythrocyte membrane protein
band 4.2) (Additional data file 2).
Discussion
To delineate the mechanisms involved in the development of
hemangioblasts from murine ES cells, Lugus et al. [26] per-
formed global gene expression profiling of mouse Flk1+ cells
that can form BL-CFCs. However, no such analysis has been
reported for the human counterpart due to availability of such
cells. In the present study, we carried out a large scale tran-
scriptional l analysis to profile undifferentiated hESCs, early
stage EBs, and BCs as an initial effort to understand the dif-
ferentiation program of hESCs towards hemangioblasts. The
availability of a well-annotated genome database for hESCs,
EBs and BCs will provide a foundation that allows one to map
and identify genes involved in human hemangioblast devel-
opment, and to optimize conditions for efficient generation of
hemangioblasts from hESCs. Our studies in general are con-
sistent with previous reports that a cluster of genes (OCT4,
NANOG) expressed at significantly high levels in hESCs were
down-regulated in early stage EBs and BCs [23,58-63],
whereas some genes restricted to endothelial and hematopoi-
etic cells (neuropilins, LMO2, GATA1 and 2, TAL1/SCL and
globins) were up-regulated dramatically in BCs and even in
early stage EBs [2,23,26,64].
Disaccharide metabolism 3 3.86E-02
Enzyme linked receptor protein signaling pathway 24 3.96E-02
Heart development (heart development) 6 4.09E-02
This comparison identified the most number of genes and had the most diverse gene ontologies.
Table 6 (Continued)
Gene ontologies for up-regulated processes in BCs versus stromal cells
Ingenuity pathway analysis shows a network of genes expressed in EB and BC data sets from the level II analysisFi ure 4
Ingenuity pathway analysis shows a network of genes expressed in EB and BC data sets from the level II analysis. This network contains nodes (genes/gene 
products) and edges (relationships between the nodes). The shaded genes, known as focus genes, were identified by microarrays and are the starting point 
to generate the network. The asterisks indicate that duplicates were identified in each dataset. The EB data set contains a network of genes (VEGF, 
GATA4, BMP4) that are interconnected and involved in blood vessel development (VEGF), heart development (GATA4), and cellular development 
(BMP4). The BC data set identified a network of genes involved in cardiovascular development (SHH, RARB, TBX5, WNT11) acting through GATA4. The 
intensity of the node color indicates the degree of expression. Nodes are displayed using various shapes that represent the functional class of the gene 
product (diamond-enzymes, ovals-transcription factors, triangles-kinase, circles-others). A solid line indicates a direct interaction while a dashed line 
indicates an indirect interaction. A line without an arrowhead indicates binding and a plus sign indicates that othernetworks contain this gene product.Genome Biology 2007, 8:R240
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Ingenuity pathway analysis identified a network of genes expressed in EB and BC data sets associated with VEGF. In the EB data set, VEGF is associated 
with 35 'focus' genes, including KDR, FLT1, NRP1, and NRP2. In the BC data set, 13 focus genes were associated with VEGF, even though it is not present 
in the data set. The intensity of the node color indicates the degree of expression. Nodes are displayed using various shapes that represent the functional 
class of the gene product (diamond-enzymes, ovals-transcription factors, triangles-kinase, circles-others). A solid line indicates a direct interaction while a 
dashed line indicates an indirect interaction. A line without an arrowhead indicates binding and a plus sign indicates that othernetworks contain this gene 
product.
Ingenuity pathway analysis of a network of genes expressed in EB and BC data sets associated with GATA2Fi ure 6
Ingenuity pathway analysis of a network of genes expressed in EB and BC data sets associated with GATA2. In the EB data set, the GATA2 network 
contained EPOR, TAL1, TCF3 and PITX2. In the BC data set, the GATA2 network contained the hemangioblastic and hematopoeitic genes TAL1, LMO2, 
FOG/ZFPM1, IGTA2B/CD41/GPIIb, and GATA1. The intensity of the node color indicates the degree of expression. Nodes are displayed using various 
shapes that represent the functional class of the gene product (diamond-enzymes, ovals-transcription factors, triangles-kinase, circles-others). A solid line 
indicates a direct interaction while a dashed line indicates an indirect interaction. A line without an arrowhead indicates binding and a plus sign indicates 
that othernetworks contain this gene product.Genome Biology 2007, 8:R240
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genitor population of cells capable of forming hemangiob-
lasts, and hematopoietic and endothelial cells [21]. To assess
the heterogeneous populations in BCs, comparisons to pub-
licly available data sets were performed in silico. Biologically
relevant comparisons allowed us to mask particular genetic
signatures within the heterogeneous population, allowing us
to identify others, such as myogenic, vasculogenic, and
hematopoietic progenitors within BCs. Our level I analysis
compared hESCs to their differentiated progeny, providing a
kinetic-like relationship of gene expression. When comparing
the hESCs to BCs, many of the down-regulated genes were
involved in development, cell differentiation, and morpho-
genesis. The predominant up-regulated genes identified in
this level I analysis were those involved in the development of
hemangioblasts and primitive erythroblasts. These genes
include those encoding the transcription factors TAL1/SCL,
LMO2 and GATA1 and 2, heme synthesis genes, genes encod-
ing erythroblast membrane proteins, and embryonic and fetal
globin genes, but very low levels of adult globin gene, suggest-
ing the yolk sac primitive status of BCs. This observation is
consistent with findings obtained from both mouse and
zebrafish models, in which hemangioblasts were first
developed from primitive streaks and yolk sacs [65,66]. The
results may also represent the fact that BC expansion medium
contains several hematopoietic cytokines, which could push
the developmental pathway towards the hematopoietic line-
age, although BCs harvested at day 6 retain the potential of
differentiating into endothelial cells under appropriate
conditions [21]. Optimization of BC expansion conditions
would, therefore, be valuable to keep these cells bipotential.
When applying this technique of multiple tissue type compar-
isons, some of the genes that are identified as 'up-regulated'
in our tissue of interest could be 'under expressed' in the ref-
erence tissue. We controlled for this by filtering for those
'under expressed' genes with a comparison to a genotypically
similar but different tissue type. For example, in our level II
analysis, we identified those genes that are up-regulated in
BCs relative to breast epithelial cells (3,700 genes) and then
removed those genes that were up-regulated in hESCs
relative to epithelial cells (2,735 genes). This removed 965
genes that could be thought of as being up-regulated in both
BCs and hESCs relative to breast epithelium or as genes that
are under-expressed in breast epithelium. GO analysis of this
data set identified cell cycle genes as the predominant theme.
This observation correlates with their biology because the
BCs and hESCs are actively dividing cells in vitro, while the
breast epithelium comprises relatively senescent cells freshly
isolated from in vivo. Most importantly, we did not identify
any tissue specific processes that we would expect to find in
BCs.
GO analysis of the genes up-regulated in BCs with respect to
epithelial cells after filtering out those that are up-regulated
in hESCs relative to breast epithelial cells identified biological
themes involved in erythropoiesis, as in the level I analysis
(heme and porphyrin biosynthesis), but also the angiogenic
components of coagulation, and synapses. This analysis iden-
tified genetic signatures representative of not just erythro-
cytes, as in the above level I analysis, but also the other
cellular components of the BC population, such as muscle,
cardiac, and hematopoietic cells and hemangioblasts. This in
silico comparison to a biologically distinct reference tissue
and filtering allows one to identify statistically significant
genes that might otherwise be missed within a heterogeneous
population.
In the level III analysis, biologically relevant comparisons
were made in silico to adjust for particular cell types repre-
sented in the BC population. As in the level II analysis, this
analysis also identified genetic signatures of the erythrocytic
population in addition to other cellular components of BCs.
When BCs were compared to leukocytes in silico, we identi-
fied a genetic signature representative of vasculogenesis,
endothelia, neurons/synapses, hemangioblasts, and erythro-
cytes, with the relative absence of leukocyte genes. When BCs
were compared to endothelia in silico, we identified a signa-
ture of erythrocytic and developmental genes with the relative
absence of the vasculogenic signature. When BCs were com-
pared to stromal cells in silico, we identified processes
involved in hematopoiesis, synapses, angiogenesis/endothe-
lia, development and more genes involved in cardiomyogene-
sis. Although EASE analysis for both epithelial and stromal
comparisons identified similar heart GO terms, the stromal
comparison identified different heart development genes. We
believe that the epithelial comparison revealed more of the
mesodermal aspect of BCs while the stromal comparison
masked the mesodermal components and revealed more car-
diomyocytic genes.
It has been shown that murine BL-CFCs are able to differen-
tiate into hematopoietic, endothelial and smooth muscle
cells, but failed to give rise to cardiomyocytes [67]. Molecular
analyses showed that BL-CFCs expressed genes indicative of
the hematopoietic and endothelial lineages, but not cardio-
myocytes [26]. Kattman et al. [68] recently identified a cardi-
ovascular progenitor with the same phenotype as the BL-CFC
progenitor, brachyury+ and Flk-1+ cells from day 4.25 EBs
(one day later than the BL-CFC progenitor) derived from
mouse ESCs. These studies strongly suggest that BL-CFCs
and cardiomyocytes, at least in the mouse ESC system, are
derived from two different progenitors. Two other studies
demonstrate the existence of multipotential progenitors for
cardiomyocytes and muscle cells, but with different surface
markers [69,70]. In the present study, several genes
restricted to cardiomyocytes or their progenitor were
detected with relatively high levels of expression in BCs. This
observation suggests that human BCs may posses the poten-
tial to differentiate into cardiomyocytes, which will need fur-
ther investigation. Alternatively, the purified BCs from
multiple colonies could contain dissimilar blast clones origi-Genome Biology 2007, 8:R240
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may have the potential to develop into cardiomyocytes, as
demonstrated recently by three groups in the mouse ESC sys-
tem [68-70]. Simultaneous isolation and characterization of
functionally distinct colonies and analysis of gene expression
in these colonies might serve to determine whether human
BCs posses the potential to differentiate into hematopoietic,
endothelial and cardiomyocyte lineages.
Conclusion
The identification and characterization of cell types within a
heterogeneous population will be of increasing importance in
stem cell research since differentiation protocols require the
formation of progenitors through a multi-stage approach.
Our previous study has shown that BCs contain a mixed pro-
genitor population of cells capable of forming hemangiob-
lasts, and hematopoietic and endothelial cells [21]. To assess
the heterogeneous populations in BCs, comparisons to pub-
licly available data sets were performed in silico. Biologically
relevant comparisons allowed us to mask particular genetic
signatures within the heterogeneous population, allowing us
to identify others, such as myogenic, vasculogenic, and
hematopoietic progenitors, within BCs. The significance of
this microarray study is in its ability to assess and identify cel-
lular populations within a heterogeneous population through
biologically relevant in silico comparisons of publicly availa-
ble data sets. In conclusion, multiple in silico comparisons
were necessary to characterize tissue-specific genetic signa-
tures within a heterogeneous hemangioblast population.
Materials and methods
hESC culture and BC growth
Culture of hESCs and growth of BCs were as reported previ-
ously [21]. In brief, undifferentiated hESCs (H1, H9) were cul-
tured with inactivated mouse embryonic fibroblast cells in
complete hESC media until they reached 80% confluence.
Undifferentiated hESCs were dissociated by 0.05% trypsin-
0.53 mM EDTA (Invitrogen, Carlsbad, CA, USA) for 2-5 min-
utes and collected by centrifugation at 1,000 rpm for 5
minutes. To induce hemangioblast precursor (mesoderm)
formation, hESCs (2-5 × 105 cells/ml) were plated on ultra-
low dishes (Corning, Corning, NY, USA) in Stemline II media
with the addition of BMP4 and VEGF165 (50 ng/ml; R&D Sys-
tems (Minneapolis, MN, USA)) and cultured in 5% CO2. Forty
eight hours later, half the media was removed and fresh
medium was added with the same final concentrations of
BMP4 and VEGF, plus SCF, Tpo and FLT3 ligand (20 ng/ml;
R&D Systems), and PTD-HoxB4 (1.5 μg/ml) to expand out
BCs and their precursor. After 3.5 days, EBs were collected
and dissociated by 0.05% trypsin-0.53 mM EDTA (Invitro-
gen) for 2-5 minutes, and a single cell suspension was pre-
pared by passing through a 22G needle 3-5 times. To expand
BCs, a single cell suspension derived from differentiation of
2-5 × 105 hESCs were mixed with 2 ml hemangioblast expan-
sion medium plated on ultra-low dishes and incubated at
37°C in 5% CO2 for 6 days, and BCs were then collected and
subjected to RNA isolation.
Affymetrix GeneChip analysis
Total RNA was isolated from purified BCs, day 3.5 EBs and
undifferentiated ESCs (from two hESC lines, H1 and H9)
using the Qiagen (Valencia, CA, USA) RNAeasy kit and ampli-
fied as previously described [21]. A total of six microarrays
were performed (two biological replicates per time point
using different hESC lines). Fragmented antisense cRNA was
used for hybridizing with human U133 Plus 2.0 arrays
(Affymetrix, Inc. Santa Clara, CA, USA) at the Core Genomic
Facility of University of Massachusetts. The validation of dif-
ferentially expressed genes was confirmed by immunocyto-
chemistry in our previous studies [21] and by semi-
quantitative RT-PCR analyses (Figure 1). The data discussed
in this publication have been deposited in NCBI's Gene
Expression Omnibus (GEO) [71] and are accessible through
GEO series accession numbers GSE8884 and GSE9196, in
accordance with MIAME standards. The demographics of the
publicly available GeneChip data sets are breast-derived epi-
thelial cells (n = 7), leukocytes (n = 6), prostate-derived
endothelial cells (n = 5), and prostate-derived stromal cells (n
= 5). These samples were chosen based on their homogeneity
(cells were immunoselected or enriched) and the number of
replicates. These data sets were downloaded from the NCBI's
GEO and are accessible through accession numbers GSE9086
(breast-derived epithelial cells), GSE9091 (leukocytes),
GSE9090 (stromal), and GSE9089 (endothelia).
Data analysis
Raw CEL files were provided by the Core Genome Facility of
the University of Massachusetts and were then analyzed with
a software package AffylmGUI (Affymetrix LIMMA, Linear
Models for Microarray Data, Graphical User Interfaces)
[72,73]. Within AffylmGUI, gene expression values were
summarized with RMA. RMA adjusts for background noise,
performs a quantile normalization, transforms the data into
log base 2, and then summarizes the multiple probes into one
intensity [74-76]. Quantification of relative differences in
gene expression among the groups of interest was accom-
plished using AffylmGUI, the sister package of limmaGUI
[72,73]. AffylmGUI reads the raw Affymetrix CEL files
directly, summarizes the gene expression values using RMA,
and then uses LIMMA to identify statistically significant dif-
ferences in gene expression [77]. LIMMA fits a linear model
for every gene (like ANOVA or multiple regression analysis),
and adjusts P values for multiple testings [77]. Differentially
expressed genes were identified with a B statistic >0. The B
statistic, also known as a likelihood of odds (LOD) score is a
moderated t-statistic with posterior residual standard devia-
tions. Subsequent analyses were performed in Microsoft
Excel and Microsoft Access.Genome Biology 2007, 8:R240
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The application Expression Analysis Systematic Explorer
(EASE) was used to determine biologically relevant themes in
a list of differentially expressed genes. EASE identifies over-
represented biological themes in terms of their GO [78]. GO
was developed to provide consistent descriptions of genes in
terms of biological processes and molecular function. Genes
with a B value >0 are incorporated into EASE where each
gene is matched to all possible GOs. The results of this analy-
sis are compared to all possible GOs for all genes on the
microarray platform and calculates a P value, based on a con-
servative variant of the Fischer's exact probability test. We
selected those pathways/processes with P < 0.05.
DAVID
DAVID (Database for Annotation, Visualization and Inte-
grated Discovery) provides tools and statistical methods for
uncovering enriched processes and pathways within diverse
and disparate gene lists [79]. DAVID also identifies over-rep-
resented biological themes in terms of their GO [78] and pro-
vides tools to visualize the distribution of genes on BioCarta
and KEGG pathway maps.
GenMapp
GenMapp is designed to visualize gene expression data on
maps representing biological pathways and grouping of
genes. It consists of hundreds of pre-made pathway maps and
is used to identify pathway level changes amongst multiple
data sets [80]. In this program, data sets are assigned a color
corresponding to cell type and the direction of gene expres-
sion changes.
Ingenuity
Networks were constructed using Ingenuity Pathways Analy-
sis (Ingenuity® Systems, Redwood City, CA, USA). A data set
containing gene identifiers of genes with a B > 0 was uploaded
into the applications. These genes, called focus genes, were
overlaid onto a global molecular network developed from
information contained in the Ingenuity Pathway Knowledge
Base. Networks of these focus genes were then algorithmi-
cally generated based on their connectivity. Each network is a
graphical representation of the molecular relationships
between genes/gene products. Genes or gene products are
represented as nodes, and the biological relationship between
two nodes is represented as an edge (line). All edges are sup-
ported by at least 1 reference from the literature stored in the
Ingenuity Pathways Knowledge Base. The intensity of the
node color indicates the degree of expression. Nodes are dis-
played using various shapes that represent the functional
class of the gene product (diamond-enzymes, ovals-transcrip-
tion factors, triangles-kinase, circles-others). A solid line
indicates a direct interaction while a dashed line indicates an
indirect interaction. A line without an arrowhead indicates
binding and a plus sign indicates that othernetworks contain
this gene product.
RNA isolation and gene expression quantification by 
semi-quantitative PCR
Total RNA was isolated from hESCs, day 3 EBs and heman-
gioblasts (BCs) using an RNAeasy Mini Kit (Qiagen) following
the procedure recommended by the supplier with DNase I
digestion, which eliminates the contamination of genomic
DNA. RNA was subjected to first-strand cDNA synthesis with
SMART II and CDS primers (Clontech, Mountain View, CA,
USA), using Superscript II reverse transcriptase (Invitrogen),
and cDNA pools were constructed using the SMART cDNA
synthesis kit (Clontech) as described previously [2,81].
Complementary DNA pools generated by the SMART proce-
dure have been shown to preserve the relative abundance
relationship of the original mRNA populations [82-84]. The
Table 7
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hemangioblasts were adjusted to equal amounts based on the
relative expression level of the hypoxanthine phosphoribosyl-
transferase gene (HPRT) and gene expression quantification
by semi-quantitative PCR was performed as described previ-
ously [2,81]. The sense and anti-sense primer sequences, and
the corresponding cDNA PCR product sizes, are shown in
Table 7. The conditions for PCR amplification were as
described with annealing temperatures and concentrations of
MgCl2 for each specific gene as shown below. PCR products
(10 μl) were separated on 1.5 to 2.0% agarose gel and visual-
ized by ethidium bromide staining. The relative expression
levels in cDNA from hESCs, EBs and hemangioblasts were
estimated visually.
Direct and indirect comparison of microarray data of 
differentially expressed genes
The direct analysis (level I) consists of making comparisons
between ESCs, EBs, and BCs. Since there are two possible
comparisons for each cell type, for example, ESCs relative to
EBs or ESCs relative to BCs, fold changes were determined by
comparing each to a cell type that did not detect the gene in
question. Fold change levels for Oct-4 and Nanog were deter-
mined by comparing ESCs to BCs and EBs to BCs. Fold
change levels for Gata-2 were determined by comparing EBs
to ESs and BCs to ESs. Fold change levels for SCL/Tal1 were
determined by comparing BCs to ESCs. Fold change levels for
γ/ε-globin were determined by comparing BCs to EBs. For the
indirect (level II) analysis, fold changes were simply deter-
mined by comparing each cell type to breast epithelia. If more
than one probe-set was identified as differentially expressed,
fold changes were averaged.
Abbreviations
BC, blast cell; BL-CFC, blast colony forming cell; DAVID,
Database for Annotation, Visualization and Integrated Dis-
covery; EASE, Expression Analysis Systematic Explorer; EB,
embryoid bodie; ESC, embryonic stem cell; GEO, Gene
Expression Omnibus; GO, gene ontology; h, human; RMA,
robust multi-chip average.
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Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a figure showing
a GenMAPP generated embryonic stem cell pathway that cor-
responds to genes enriched in ESCs (green), EBs (orange) and
BCs (red) with epithelial cells as a baseline. Additional data
file 2 is a figure showing a predominant Ingenuity generated
network that was identified in all four data sets of the level III
analysis. GATA1 interacts with other nuclear genes such as
TAL1, LMO2, and KLF1, which induceeythropoetic genes
such as the hemoglobin family (HBG1, HBG2, HBE, HBB,
and HBZ), and those involved in heme synthesis (ALAS2).
Additional data files 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are
tables listing genes that were up-regulated in ESCs, EBs, or
BCs relative to each other or a specific reference tissue. Addi-
tional data file 3 contains a list of genes that are down-regu-
lated upon differentiation of ESCs into EBs. Additional data
file 4 contains a list of genes that are down-regulated upon
differentiation of ESCs into BCs. Additional data file 5 con-
tains a list of genes that are up-regulated upon differentiation
of ESCs into EBs. Additional data file 6 contains a list of genes
that are down-regulated upon differentiation of EBs into BCs.
Additional data file 7 contains a list of genes that are up-reg-
ulated upon differentiation of EBs into BCs. Additional data
file 8 contains a list of genes that are up-regulated upon dif-
ferentiation of ESCs into BCs. Additional data file 9 contains
a list of genes that are up-regulated in ESCs when compared
to breast epithelia. Additional data file 10 contains a list of
genes that are up-regulated in EBs when compared to breast
epithelia. Additional data file 11 contains a list of genes that
are up-regulated in BCs when compared to breast epithelia.
Additional data file 12 contains a list of genes that are up-reg-
ulated in BCs when compared to leukocytes. Additional data
file 13 contains a list of genes that are up-regulated in BCs
when compared to endothelial cells. Additional data file 14
contains a list of genes that are up-regulated in BCs when
compared to stromal cells. Additional data files 15, 16, 17, 18,
19, 20 are six CEL files of data from human U133 Plus 2.0
arrays (Affymetrix, Inc.) hybridized to RNA from purified
BCs, day 3.5 EBs and undifferentiated ESCs (from two hESC
lines, H1 and H9). Additional data file 15 contains a CEL file
of undifferentiated ESCs, H1-GFP labeled. Additional data
file 16 contains a CEL file of day3.5 EBs-H1 and additional
datal file 17 contains a CEL file of BC derived from H1. Addi-
tional data file 18 contains a CEL file from undifferentiated
ESCs, H9. Additional data file 19 contains a CEL file from
day3.5 EBs-H9. Additional data file 20 contains a CEL file of
BC derived from H9.
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